Skip to content

Released Aug 5, 2020, after the close

10-Q filed Aug 6, 2020, 37 days after period end · 0001564590-20-036997

Q2 2020 · 10-Q
Revenue$9.47M−10.0% vs Q2 2019+32.4% vs Q1 2020
Net Income$29.87MN/M vs Q2 2019N/M vs Q1 2020
EPS Diluted$0.94N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$16,417,000N/M
Operating Cash Flowderived-$12,500,000N/M
Margins · derived
Operating margin-173.4%−43.4 pt vs Q2 2019
Net margin315.5%+446.5 pt vs Q2 2019

What the release said

The release

Same quarter

MetricQ2 2020Q2 2019Q2 2018Q2 2017
Revenue$9.47M$10.53M$5.70M$15.36M
Net Income$29.87M-$13.79M-$11.54M-$1.81M
EPS Diluted$0.94-$0.60-$24.17-$4.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR